Travatan Z Patent Expiration

Travatan Z is a drug owned by Sandoz Inc. It is protected by 5 US drug patents filed in 2013. Out of these, 3 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 13, 2029. Details of Travatan Z's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268299 Self preserved aqueous pharmaceutical compositions
Oct, 2029

(5 years from now)

Active
US8323630 Self-preserved aqueous pharmaceutical compositions
Sep, 2027

(2 years from now)

Active
US8388941 Self preserved aqueous pharmaceutical compositions
Sep, 2027

(2 years from now)

Active
US5889052 Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
Dec, 2014

(9 years ago)

Expired
US5510383 Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
Aug, 2013

(11 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Travatan Z's patents.

Given below is the list of recent legal activities going on the following patents of Travatan Z.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 22 May, 2024 US8323630 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 06 Mar, 2024 US8268299 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 21 Aug, 2020 US8388941
Payment of Maintenance Fee, 8th Year, Large Entity 21 May, 2020 US8323630 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 05 Mar, 2020 US8268299 (Litigated)
Review Certificate Mailed 11 Jun, 2019 US8268299 (Litigated)
Review Certificate 02 May, 2019 US8268299 (Litigated)
Termination or Final Written Decision 20 Sep, 2018 US8268299 (Litigated)
Request for Trial Granted 22 Sep, 2017 US8268299 (Litigated)
Petition Entered 28 Mar, 2017 US8268299 (Litigated)


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Travatan Z and ongoing litigations to help you estimate the early arrival of Travatan Z generic.

Travatan Z's Litigations

Travatan Z been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 05, 2013, against patent number US8388941. The petitioner Apotex Corp., challenged the validity of this patent, with Alcon Research, Ltd. as the respondent. Click below to track the latest information on how companies are challenging Travatan Z's patents.

Last updated on October 1, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8268299 March, 2017 FWD Entered
(20 Sep, 2018)
Alcon Research, Ltd. Argentum Pharmaceuticals LLC
US8268299 July, 2013 Terminated-Settled
(21 Jul, 2014)
ALCON RESEARCH, LTD. Apotex Corp.
US8323630 July, 2013 Terminated-Settled
(21 Jul, 2014)
ALCON RESEARCH, LTD. Apotex Corp.
US8388941 July, 2013 Terminated-Settled
(21 Jul, 2014)
Alcon Research, Ltd. Apotex Corp.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Travatan Z's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Travatan Z's generic, the next section provides detailed information on ongoing and past EP oppositions related to Travatan Z patents.

Travatan Z's Oppositions Filed in EPO

Travatan Z has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 02, 2012, by Allergan, Inc.. This opposition was filed on patent number EP07842914A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP07842925A Mar, 2016 Pohlman, Sandra M. Patent maintained as amended
EP07842914A Aug, 2012 Pohlman, Sandra M. Patent maintained as amended
EP07842914A Aug, 2012 ALLERGAN, INC. Patent maintained as amended


US patents provide insights into the exclusivity only within the United States, but Travatan Z is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Travatan Z's family patents as well as insights into ongoing legal events on those patents.

Travatan Z's Family Patents

Travatan Z has patent protection in a total of 23 countries. It's US patent count contributes only to 20.0% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Travatan Z.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Travatan Z's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 13, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Travatan Z Generics:

Travoprost is the generic name for the brand Travatan Z. 7 different companies have already filed for the generic of Travatan Z, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Travatan Z's generic

How can I launch a generic of Travatan Z before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Travatan Z's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Travatan Z's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Travatan Z -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
0.00004 19 Feb, 2009 1 02 Dec, 2014 Extinguished

Alternative Brands for Travatan Z

Travatan Z which is used for reducing intraocular pressure in glaucoma and ocular hypertension., has several other brand drugs in the same treatment category and using the same active ingredient (Travoprost). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Alcon Pharms Ltd
Travatan

(uses Travoprost)

Used for lowering intraocular pressure in the treatment of glaucoma and ocular hypertension.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Travoprost. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Glaukos
Idose Tr
Novartis
Izba


Apart from brand drugs containing the same ingredient, some generics have also been filed for Travoprost, Travatan Z's active ingredient. Check the complete list of approved generic manufacturers for Travatan Z





About Travatan Z

Travatan Z is a drug owned by Sandoz Inc. It is used for reducing intraocular pressure in glaucoma and ocular hypertension. Travatan Z uses Travoprost as an active ingredient. Travatan Z was launched by Sandoz in 2006.

Approval Date:

Travatan Z was approved by FDA for market use on 21 September, 2006.

Active Ingredient:

Travatan Z uses Travoprost as the active ingredient. Check out other Drugs and Companies using Travoprost ingredient

Treatment:

Travatan Z is used for reducing intraocular pressure in glaucoma and ocular hypertension.

Dosage:

Travatan Z is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.004% SOLUTION/DROPS Prescription OPHTHALMIC